How to buy Neurocrine Biosciences stock (NBIX)

Neurocrine Biosciences is a drug manufacturers - specialty & generic business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $135.42 – an increase of 6.88% over the previous week. Neurocrine Biosciences employs 1,700 staff and has a trailing 12-month revenue of around $2.2 billion.

Our top picks for where to buy Neurocrine Biosciences stock

Buy Neurocrine Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Neurocrine Biosciences stock price (NASDAQ: NBIX)

Use our graph to track the performance of NBIX stocks over time.

Neurocrine Biosciences shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$135.42
52-week range	$110.95 - $157.98
50-day moving average more info button	$122.37
200-day moving average more info button	$132.99
Wall St. target price	$163.69
PE ratio more info button	36.12
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$3.75

Is it a good time to buy Neurocrine Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neurocrine Biosciences price performance over time

Historical closes compared with the close of $134.96 from 2024-12-19

1 week (2024-12-13)	6.52%
1 month (2024-11-22)	7.41%
3 months (2024-09-20)	14.03%
6 months (2024-06-21)	0.29%

1 year (2023-12-21)	11.39%
2 years (2022-12-21)	12.15%
3 years (2021-12-21)	59.40%
5 years (2019-12-20)	22.90%

Is Neurocrine Biosciences stock undervalued or overvalued?

Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Neurocrine Biosciences's P/E ratio

Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, Neurocrine Biosciences shares trade at around 36x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Neurocrine Biosciences's PEG ratio

Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3223. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Neurocrine Biosciences's EBITDA

Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $628 million.

The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.

Neurocrine Biosciences financials

Revenue TTM	$2.2 billion
Operating margin TTM	29.71%
Gross profit TTM	$1 billion
Return on assets TTM	11.8%
Return on equity TTM	16.35%
Profit margin	17.21%
Book value	$26.87
Market Capitalization more info button	$13.7 billion

TTM: trailing 12 months

Neurocrine Biosciences share dividends

We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.

Neurocrine Biosciences share price volatility

Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $110.95 up to $157.9799. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.353. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).

Neurocrine Biosciences overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc. ; Voyager Therapeutics, Inc. ; BIAL " Portela & Ca, S.

Frequently asked questions

What percentage of Neurocrine Biosciences is owned by insiders or institutions?
Currently 0.994% of Neurocrine Biosciences shares are held by insiders and 95.927% by institutions. How many people work for Neurocrine Biosciences?
Latest data suggests 1,700 work at Neurocrine Biosciences. When does the fiscal year end for Neurocrine Biosciences?
Neurocrine Biosciences's fiscal year ends in December. Where is Neurocrine Biosciences based?
Neurocrine Biosciences's address is: 12780 El Camino Real, San Diego, CA, United States, 92130 What is Neurocrine Biosciences's ISIN number?
Neurocrine Biosciences's international securities identification number is: US64125C1099 What is Neurocrine Biosciences's CUSIP number?
Neurocrine Biosciences's Committee on Uniform Securities Identification Procedures number is: 64125C109